Skip to content

D&A at other companies

Pfizer logo
PfizerPFE
$1.61B-0.3%
McKesson logo
McKessonMCK
$65M+12.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$20.92M-8.6%
AMP
Amphastar PharmaceuticalsAMPH
$8.08M+9.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$113K-18.7%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$397K+41.8%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$20.8B+92.8%
Enterprise value$33.61B+34.5%
P/S1.4×+0.7×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's D&A?
Viatris (VTRS) reported D&A of $676.1M in Q1 2026.
How has Viatris's D&A changed year-over-year?
Viatris's D&A increased by 1.7% year-over-year, from $664.7M to $676.1M.
What is the long-term trend for Viatris's D&A?
Over 4 years (2021 to 2025), Viatris's D&A has grown at a -11.2% compound annual growth rate (CAGR), from $4.51B to $2.8B.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.